Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200178 | 0.90 | CYP3A4 (0.46) | ALDH1A1CYP3A4MEN1KMT2ATRPM8 | |
| SCHEMBL27878438 | 0.87 | BTN3A1 (0.36) | ALDH1A1CYP3A4MEN1KMT2ACA12 | |
| Potassium Ion SCHEMBL1577215 | 0.85 | CYP3A4 (0.35) | ALDH1A1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL1577218 | 0.85 | BTN3A1 (0.35) | ALDH1A1CYP3A4MEN1KMT2ACA12 | |
| SCHEMBL5053329 | 0.84 | TDP1 (0.36) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL28448143 | 0.83 | ALDH1A1 (0.39) | ALDH1A1CYP3A4MEN1KMT2ATRPM8 | |
| SCHEMBL3627115 | 0.82 | CYP3A4 (0.41) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL5908971 | 0.81 | ALDH1A1 (0.38) | ALDH1A1CYP3A4MEN1KMT2ATRPM8 | |
| SCHEMBL5908953 | 0.81 | TSHR (0.59) | ALDH1A1CYP3A4MEN1KMT2ATRPM8 | |
| SCHEMBL21437072 | 0.81 | ALDH1A1 (0.38) | ALDH1A1CYP3A4MEN1KMT2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188050-A1 | RECOMBINANT POLYPEPTIDES WITH BERBERINE BRIDGE ENZYME ACTIVITY USEFUL FOR THE BIOSYNTHESIS OF CANNABINOIDS | INVIZYNE TECHNOLOGIES, INC. (US) | 2025-06-12 | — | — | US | claimed |
| US-12084689-B2 | Prenyltransferase variants with increased thermostability | INVIZYNE TECHNOLOGIES, INC. (US) | 2024-09-10 | — | — | US | claimed |
| EP-4347800-A1 | PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITY | Invizyne Technologies, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20230348866-A1 | BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF CANNABINOIDS AND OTHER PRENYLATED COMPOUNDS | U.S. DEPARTMENT OF ENERGY | 2023-11-02 | — | — | US | claimed |
| US-20230145729-A1 | INDOLE DITERPENE BIOSYNTHESIS | GRASSLANZ TECHNOLOGY LIMITED (NZ) | 2023-05-11 | — | — | US | claimed |
| US-20230098978-A1 | PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITY | INVIZYNE TECHNOLOGIES, INC. (US) | 2023-03-30 | — | — | US | claimed |
| EP-4125340-A1 | INDOLE DITERPENE BIOSYNTHESIS | Grasslanz Technology Limited (NZ) | 2023-02-08 | — | — | EP | claimed |
| US-20220403349-A1 | PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITY | INVIZYNE TECHNOLOGIES, INC. (US) | 2022-12-22 | — | — | US | claimed |
| US-11518983-B1 | Prenyltransferase variants with increased thermostability | INVIZYNE TECHNOLOGIES, INC. (US) | 2022-12-06 | — | — | US | claimed |
| WO-2022251285-A1 | PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITY | INVIZYNE TECHNOLOGIES, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| US-6284506-B1 | MOLECULAR HYBRIDIZATION; CAROTENOID AND ASTAXANTHIN PRODUCTION; GENE EXPRESSION OF MELAVONATE OR ISOPENTENYL TO FARNESYL PYROPHOSPHATE BIOSYNTHETIC ENZYMES | ROCHE VITAMINS INC. | 2001-09-04 | — | — | US | claimed |
| US-6225096-B1 | AMINO ACID SEQUENCE HAVING AMINO ACID TYROSINE AT POSITION 81 REPLACED BY GLYCINE, ALANINE, SERINE, OR METHIONINE; FOR SYNTHESIZING PRENYL DIPHOSPHATES HAVING A LONGER CHAIN LENGTH | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2001-05-01 | — | — | US | claimed |
| US-6207409-B1 | CULTURING A RECOMBINANT CELL THAT HAS BEEN TRANSFORMED WITH AN EXPRESSION VECTOR HAVING A REGULATORY SEQUENCE AND A POLYNUCLEOTIDE COMPRISING A DNA SEQUENCE WHICH ENDCODES GERANYL/GERANYLPYROPHOSPHATE OF FLAVOBACTERIUM SPECIES | ROCHE VITAMINS INC. | 2001-03-27 | — | — | US | claimed |
| US-6124113-A | CULTURING IN SUITABLE MEDIUM CONTAINING FARNESYL PYROPHOSPHATE AND ISOPENTYL PYROPHOSPHATE UNDER CONDITIONS SUFFICIENT FOR EXPRESSION OF ENZYMES WHICH CATALYZE CONVERSION OF THE FARNESYL AND ISOPENTYL PYROPHOSPHATES TO ZEAXANTHIN | ROCHE VITAMINS INC. (US) | 2000-09-26 | — | — | US | claimed |
| WO-2000044912-A1 | MANIPULATING ISOPRENOID EXPRESSION | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2000-08-03 | — | — | WO | claimed |
| EP-0889952-A1 | GENES OF CAROTENOID BIOSYNTHESIS AND METABOLISM AND A SYSTEM FOR SCREENING FOR SUCH GENES | UNIVERSITY OF MARYLAND COLLEGE PARK (US) | 1999-01-13 | — | — | EP | claimed |
| US-5773273-A | POLYPEPTIDE | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 1998-06-30 | — | — | US | claimed |
| US-5684238-A | Biosynthesis of zeaxanthin and glycosylated zeaxanthin in genetically engineered hosts | AMOCO CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| WO-1997036998-A1 | GENES OF CAROTENOID BIOSYNTHESIS AND METABOLISM AND A SYSTEM FOR SCREENING FOR SUCH GENES | UNIVERSITY OF MARYLAND COLLEGE PARK (US) | 1997-10-09 | — | — | WO | claimed |
| US-5545816-A | DNA SEGMENTS ENCODING THE ERWINIA HERBICOLA ENZYMES GERANYLGERANYL PYROPHOSPHATE SYNTHASE AND PHYTOENE SYNTHASE | AMOCO CORPORATION (US) | 1996-08-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145729-A1 | INDOLE DITERPENE BIOSYNTHESIS | INMT, PNMT, COASY | ALDH1A1 3947/4885CYP3A4 1811/4885MEN1 3622/4885 |
| US-20250188050-A1 | RECOMBINANT POLYPEPTIDES WITH BERBERINE BRIDGE ENZYME ACTIVITY USEFUL FOR THE BIOSYNTHESIS OF CANNABINOIDS | COASY, CBR1, CBR3 | ALDH1A1 2470/4885CYP3A4 339/4885MEN1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.